Premium
MAINTENANCE THERAPY FOR DUODENAL ULCER—A TRIAL COMPARING CIMETIDINE WITH A PROSTAGLANDIN SYNTHETASE PROMOTER
Author(s) -
Dew M. J.,
Harries A. D.,
Hughes P.,
Keeling S.,
FentonMay V.,
Rhodes J.
Publication year - 1984
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/j.1365-2710.1984.tb01099.x
Subject(s) - cimetidine , prostaglandin , duodenal ulcer , medicine , gastroenterology , maintenance therapy , pharmacology , chemotherapy
SUMMARY The effect of treatment on maintenance of remission was examined in 90 patients with healed duodenal ulcer shown by endoscopy. They were randomized to take treatment for 6 months with a prostagland in synthetase promoter (263E) 500 mg three times daily or cimetidine 400 mg at night or an identical placebo. Sixty‐five patients completed the trial or had a relapse of symptoms. The percentage of patients who had recurrent ulcers or duodenitis alone on endoscopy was 29% on 263E, 36% with cimetidine, and 50% on placebo. These figures did not differ significantly. Trials of this design are now difficult to conduct because patients take an H2 receptor antagonist soon after recurrence of symptoms, before their next clinic appointment.